|
Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide |
Liubao P, Xiaomin W, Chongqing T, Karnon J, Gannong C, Jianhe L, Wei C, Xia L, Junhua C |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Liubao P, Xiaomin W, Chongqing T, Karnon J, Gannong C, Jianhe L, Wei C, Xia L, Junhua C. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. PharmacoEconomics 2009; 27(10): 873-886 Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Breast Neoplasms /economics /therapy; Chemotherapy, Adjuvant /economics; China; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide /administration & Doxorubicin /administration & Female; Humans; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Taxoids /administration & dosage; dosage; dosage AccessionNumber 22009103784 Date bibliographic record published 04/08/2010 |
|
|
|